DMII — Drugs Made In America Acquisition II Cashflow Statement
0.000.00%
Last trade - 00:00- $640.82m
- $640.92m
Annual cashflow statement for Drugs Made In America Acquisition II, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2024 December 31st | 2025 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K |
| Standards: | USG | USG |
| Status: | Final | Final |
| Net Income/Starting Line | -0.152 | 4.19 |
| Non-Cash Items | — | -4.6 |
| Unusual Items | ||
| Other Non-Cash Items | ||
| Changes in Working Capital | -0.043 | -0.608 |
| Change in Accounts Receivable | ||
| Change in Prepaid Expenses | ||
| Change in Accounts Payable | ||
| Change in Accrued Expenses | ||
| Cash from Operating Activities | -0.389 | -2.04 |
| Other Investing Cash Flow Items | — | -500 |
| Purchase of Investments | ||
| Cash from Investing Activities | — | -1,000 |
| Financing Cash Flow Items | -0.074 | 502 |
| Other Financing Cash Flow | ||
| Net Issuance / Retirement of Stock | ||
| Net Issuance / Retirement of Debt | ||
| Cash from Financing Activities | 0.423 | 1,002 |
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | 0.017 | -0.017 |